Stratpharma USA Brings Stratpharma AG’s Innovative Wound Care Products To The U.S. Market Stratpharma

SAN DIEGO--(BUSINESS WIRE)--Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company that specializes in innovative film-forming full-contact topical medical products to improve medical and aesthetic outcomes in post-procedure care in aesthetic dermatology, plastic surgery, and oncology, recently announced the U.S. availability of Stratpharma’s wound care and scar management portfolio. Stratpharma Inc. USA will focus on informing and educating the U.S. medical community, including dermatologists, plastic surgeons, radiation oncologists, and OBGyns, as to how these novel topical medical devices can help advance patient outcomes and quality of life. Stratpharma’s groundbreaking products are listed by the U.S. Food and Drug Administration (FDA).

Stratpharma’s cutting-edge film-forming wound care and scar management range is comprised of:

• Stratacel, an advanced film-forming wound dressing developed specifically for sensitive skin areas including the periorbital region, lips, and nostrils. Stratacel is especially effective for laser resurfacing procedures.
• Stratamed, the first film-forming gel based wound dressing approved for the immediate use on open wounds and compromised skin. A breakthrough treatment in wound and post-procedure care, Stratamed can be applied immediately after all dermatological interventions including burns (1^st and 2^nd degree burns; 3^rd degree burns after the presence of granulating tissue) for rapid re-epithelialization and abnormal scar management.
• Strataderm, the only once-per-day topical application for scar management. Strataderm is a rapidly drying, non-sticky, transparent, silicone gel formulation for the treatment of both old and new scars, as well as abnormal scar management, in the form of hypertrophic scars and keloids.

Stratpharma also plans to introduce Stratamark, a new product for the treatment and prevention of stretch marks, in the near future, with U.S. clinical trials currently underway.

“Stratpharma is revolutionizing wound and post-procedure care. We are committed to supporting the health care community and patients, advancing clinical outcomes and quality of life, while providing the highest standards of service,” said James Kone Jr., Executive Vice President of Sales & Business Development at Stratpharma Inc. USA.

Stratpharma products are available in the U.S. to patients exclusively through their physician. For more information on Stratpharma Inc. USA and Stratpharma products, please visit www.stratpharma.com.

About Stratpharma

Stratpharma Inc. USA is a U.S. subsidiary of Stratpharma AG, the Swiss company that specializes in innovative film-forming full-contact topical medical products to improve medical and aesthetic outcomes in post-procedure care in aesthetic dermatology, plastic surgery, and oncology. Headquartered in San Diego, California, Stratpharma Inc. USA is responsible for bringing product distribution and education to U.S. healthcare professionals and patients. In addition to the U.S., Stratpharma products are registered in more than 80 countries and sold in over 50 countries all over the world. For more information, visit www.stratpharma.com or call Stratpharma Inc. USA at 619.930.5788.